209 related articles for article (PubMed ID: 30468672)
21. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
22. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
Jiang X; Zhang W; Li L; Xie S
Pathol Oncol Res; 2021; 27():1609985. PubMed ID: 34737677
[TBL] [Abstract][Full Text] [Related]
23. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
Li L; Yu S; Hu Q; Hai Y; Li Y
Int J Biol Sci; 2021; 17(12):3133-3144. PubMed ID: 34421355
[TBL] [Abstract][Full Text] [Related]
24. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
25. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
26. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
27. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.
Zhang PF; Wang F; Wu J; Wu Y; Huang W; Liu D; Huang XY; Zhang XM; Ke AW
J Cell Physiol; 2019 Mar; 234(3):2788-2794. PubMed ID: 30132868
[TBL] [Abstract][Full Text] [Related]
28. Non-coding RNA in drug resistance of hepatocellular carcinoma.
Ding B; Lou W; Xu L; Fan W
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30224380
[TBL] [Abstract][Full Text] [Related]
29. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
31. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
[No Abstract] [Full Text] [Related]
32. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Kuczynski EA; Yin M; Bar-Zion A; Lee CR; Butz H; Man S; Daley F; Vermeulen PB; Yousef GM; Foster FS; Reynolds AR; Kerbel RS
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27059374
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
Awan FM; Naz A; Obaid A; Ikram A; Ali A; Ahmad J; Naveed AK; Janjua HA
Sci Rep; 2017 Sep; 7(1):11448. PubMed ID: 28904393
[TBL] [Abstract][Full Text] [Related]
35. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
Pang L; Xu L; Yuan C; Li X; Zhang X; Wang W; Guo X; Ouyang Y; Qiao L; Wang Z; Liu K
Mol Carcinog; 2019 Nov; 58(11):2118-2126. PubMed ID: 31465134
[TBL] [Abstract][Full Text] [Related]
36. Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
Masuda M; Chen WY; Miyanaga A; Nakamura Y; Kawasaki K; Sakuma T; Ono M; Chen CL; Honda K; Yamada T
Mol Cell Proteomics; 2014 Jun; 13(6):1429-38. PubMed ID: 24643969
[TBL] [Abstract][Full Text] [Related]
37. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
38. miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
Liu K; Liu S; Zhang W; Ji B; Wang Y; Liu Y
Int J Oncol; 2014 Oct; 45(4):1537-46. PubMed ID: 25096647
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
Yuan W; Tao R; Huang D; Yan W; Shen G; Ning Q
Aging (Albany NY); 2021 Jan; 13(3):3969-3993. PubMed ID: 33495404
[TBL] [Abstract][Full Text] [Related]
40. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]